Portal‐systemic shunts for Budd‐Chiari syndrome

Marshall J. Orloff – 1 November 1987 – Nine patients with Budd‐Chiari syndrome (BCS) were treated by a portal systemic shunt. One had thrombosis of the superior mesenteric vein (SMV) and another had complete obstruction of the retrohepatic inferior vena cava (IVC). All other patients had a marked stenosis of the retrohepatic IVC with caval pressure ranging from 12 to 24 mmHg (mean: 17 mmHg). Seven patients had an interprosition mesocaval shunt using an autologous jugular vein. The patient with a thrombosed SMV had a portoartial shunt.

Acute non‐B hepatitis in the Israel defence forces: Comparison of some epidemiologic features before and after the usage of preexposure immune serum globulin prophylaxis

Haim Matzkin – 1 November 1987 – Large‐scale epidemics of non‐B (HBsAg‐negative) hepatitis have occurred in the Israel Defense Forces prior to post‐ and preexposure immune serum globulin administration. Presently, hepatitis morbidity rates have stabilized around 1 to 2 per 1,000. Several years after vaccine initiation, a comparison of epidemiological features was made in order to redefine risk groups.

Lactitol vs. lactulose in the treatment of acute hepatic encephalopathy in cirrhotic patients: A double‐blind, randomized trial

Marsha Y. Morgan, Katherine E. Hawley – 1 November 1987 – Lactitol (β‐galactosido‐sorbitol) is a nonabsorbable disaccharide available as a powder which, in open comparison, is as effective as lactulose in the treatment of chronic hepatic encephalopathy, but is better tolerated. Twenty‐five cirrhotic patients experiencing 28 episodes of acute hepatic encephalopathy were randomized blindly to treatment with either lactitol (n = 15) or lactulose (n = 13).

Biochemical characteristics of isolated rat liver stellate cells

Masao Yamada, William S. Blaner, Dianne Robert Soprano, Joseph L. Dixon, Hild M. Kjeldbye, Dewitt S. Goodman – 1 November 1987 – Hepatic stellate cells play a quantitatively important role in hepatic retinoid metabolism and storage in rats maintained under normal nutritional conditions. Studies were conducted to further explore the biochemical characteristics of hepatic stellate cells. Stellate cells were isolated in high purity and yield from the livers of normal rats.

The protective effects of prostaglandin E1 in an experimental massive hepatic cell necrosis model

Yasuhiro Mizoguchi, Hiroko Tsutsui, Keiji Miyajima, Yoshihide Sakagami, Shuichi Seki, Kenzo Kobayashi, Sukeo Yamamoto, Seiji Morisawa – 1 November 1987 – When a small amount of Gram‐negative lipopolysaccharide was intravenously injected into mice which had been injected with heat‐killed Propionibacterium acnes 7 days before, massive hepatic cell necrosis was induced and most of the mice died 24 hr later. However, when prostaglandin E1 was administered with lipopolysaccharide, remarkable improvements in the survival rate and in the histological changes of the liver were observed.

Changes in the cytokeratin intermediate filament cytoskeleton associated with mallory body formation in mouse and human liver

Y. Katsuma, S. H. H. Swierenga, U. Khettry, N. Marceau, S. W. French – 1 November 1987 – Mouse and human extracted liver tissue were examined by indirect immunofluorescent staining and transmission electron microscopy in order to study the alteration of cytokeratin intermediate filaments associated with Mallory body formation. Frozen sections of griseofulvin‐fed mouse liver and human liver of primary biliary cirrhosis and primary sclerosing cholangitis were extracted by Triton X‐100 and nuclease.

Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: A second type of “autoimmune” hepatitis

Jean‐Claude Homberg, Nisen Abuaf, Olivier Bernard, Shamsul Islam, Fernando Alvarez, Samir H. Khalil, Raoul Poupon, François Darnis, Victor‐Georges Lévy, Patrick Grippon, Pierre Opolon, Jacques Bernuau, Jean‐Pierre Benhamou, Daniel Alagille – 1 November 1987 – Sixty‐five patients with histologically proven chronic active hepatitis of unknown cause but associated with the antiliver/kidney microsome antibody type 1, confirmed by immunofluorescence and immunoprecipitation, were selected as forming a special entity.

Subscribe to